Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2CNS 2Genitourinary 1Gastrointestinal 1

Conditions

Sarcoma, Ewing 4Rhabdomyosarcoma 4Osteosarcoma 4Recurrence 2Neuroblastoma 2Wilms Tumor 1Sarcoma 1Rhabdoid Tumor 1Oligodendroglioma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms 1Hepatoblastoma 1Gliosarcoma 1Glioblastoma 1Astrocytoma 1

Interventions

Cyclophosphamide 23Temozolomide 14Filgrastim 13Irinotecan 12Melphalan 11Etoposide 10Carboplatin 9Vincristine 8Peripheral Blood Stem Cell Transplantation 8Granulocyte Colony-Stimulating Factor 8X-Rays 7Topotecan 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Busulfan 7fludarabine 6Thiotepa 6Phantoms, Imaging 6fludarabine phosphate 5Radiotherapy 5Biopsy 5Antilymphocyte Serum 5Oxaliplatin 4Nuclear Medicine Department, Hospital 4Nivolumab 4Methylprednisolone 4Ifosfamide 4Cisplatin 4palbociclib 3olaparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neuroblastoma × irinotecan sucrosofate × Sarcoma × Clear all
NCT04901702 2026-05-19

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

St. Jude Children's Research Hospital

Phase 1/2 Recruiting
90 enrolled
CNSGastrointestinalGenitourinarySarcoma

Neoplasms, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT02013336 2022-03-31

Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors

South Plains Oncology Consortium

Phase 1 Unknown
30 enrolled
CNSSarcoma

Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡